Thymoglobulin and Total Lymphoid Irradiation for Hematologic Malignancies

Summary

Primary Objective: 1\. To determine whether the primary endpoint: the composite success rate, defined as the proportion of patients who are alive at day 100; and are without grade 3-4 Graft versus Host Disease (GVHD); and are without grade 4 toxicity (unrelated to infection); and have engrafted, is likely to be at least 40%. Secondary Objectives: 1. To determine the cumulative incidence of chronic graft versus host disease. 2. To determine the overall and disease free survival.

Timeline

Start

2006-06

Primary completion

2009-05

Completion

2009-05

Drugs

Indications